A federal appeals court has dealt a blow to Novartis’ attempt to apply the sharp limits on punitive damages claims of its home state New Jersey to litigation over its cancer drugs Aredia and Zometa.
On Thursday in Winter v. Novartis Pharmaceuticals, the U.S. Court of Appeals for the Eighth Circuit rejected the company’s request for a new trial on that jurisdictional issue. The ruling affirmed Western District of Missouri U.S. District Judge Nanette Laughrey’s application of Missouri law to those claims.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
